Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Track and trace codes...

    Track and trace codes For Pharma APIs: Ministry issues gazette, CDSCO issues notice

    Farhat NasimWritten by Farhat Nasim Published On 2019-08-15T11:53:50+05:30  |  Updated On 15 Aug 2019 11:53 AM IST
    Track and trace codes For Pharma APIs: Ministry issues gazette, CDSCO issues notice

    New Delhi: To ensure authenticity, every Active Pharmaceutical Ingredient (API) manufactured or imported in the country will soon bear Quick Response code on its label at every level of packaging. The information will be readable with a software application to facilitate tracking and tracing.


    Confirmation to this effect was given by the apex drug regulatory body, Central Drugs Standard Control Organisation (CDSCO) after a gazette notification was published on August 9 2019.


    Medical Dialogues had earlier reported that Drugs Technical Advisory Board (DTAB), functional under the Central Drugs and Standard (CDSCO) had recommended “making it mandatory to have quick response code (QR) coding on labels of Active Pharmaceutical Ingredient (API), the most important constituent of any drug formulation for tracing the origin and movement of APIs from manufacturers to formulators through a system of networking.’’


    Also Read: Mandatory QR coding for APIs soon: DTAB

    With the recent Gazette notification issued by the Health Ministry, it will become mandatory for API manufacturers to include codes to track-and-trace key ingredients used to make medicines in India.

    In order to incorporate the same, the Drugs and Cosmetics Rules, 1945 shall be amended by the government in exercise of the powers conferred by sub-section (1) of section 12 and sub-section (1) of section 33 of the Drugs and Cosmetics Act, 1940 (23 of 1940) and in consultation with the Drugs Technical Advisory Board.


    The draft rules formulated in this regard published on the CDSCO website reads;


    In the Drugs and Cosmetics Rules, 1945, in rule 96, after sub-rule (4), following sub-rule shall be inserted, namely:-



    “(5) Every active pharmaceutical ingredient (bulk drug) manufactured or imported in India shall bear Quick Response code on its label at each level packaging that store data or information readable with software application to facilitate tracking and tracing. The stored data or information shall include the following minimum particulars, namely:-
    (i) Unique product identification code,
    (ii) Name of the API,
    (iii) Brand name (if any),
    (iv) Name and address of the manufacturer,
    (v) Batch no.,
    (vi) Batch size,
    (vii) Date of manufacturing,
    (viii) Date of expiry or retesting,
    (ix) Serial shipping container code,
    (x) Manufacturing licence no. or import licence no.
    (xi) Special storage conditions required (if any).”.

    Objections and suggestions from the stakeholders regarding the amendment have been invited wherein the said draft rules shall be taken into consideration on or after the expiry of a period of thirty days from August 9 2019.


    Objections and suggestions, if any, may be addressed to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Government of India, Room No. 414 A, D Wing, Nirman Bhavan, New Delhi - 110011 or emailed at drugsdiv-mohfw@gov.in.

    Also Read: 22-member Committee Constituted to guide CDSCO on Medical Device Regulation
    active pharmaceutical ingredientsAPICDSCODPCOdrug importsdrug packagingDrugs and Cosmetics RulesDrugs Technical Advisory BoardDTABGazette noticeGazette of Indiagovt of indiamohfw@gov.inofficial noticepharmapharma newspharma news indiaquick response codesoftware for API

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Farhat Nasim
    Farhat Nasim

      Farhat Nasim joined Medical Dialogue an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok